FDAapproval83% confidence
FDA approves zidesamtinib for ROS1-positive non-small cell lung cancer
Source: FDA
Why This Matters
Why this matters: illustrates how regulators handled a comparable approval decision relevant to AstraZeneca.
Regulatory Analysis
On July 22, 2026, the Food and Drug Administration approved zidesamtinib (Jideytro, Nuvalent, Inc.) for adults with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC) who received at least one prior ROS1 tyrosine kinase inhibitor (TKI).
Supporting Context
- Therapeutic area
- Oncology · PARP Inhibitor
- Sub-indication
- General
Related signal: AstraZeneca initiates post-marketing surveillance for Lynparza in South Korea